United States Patent 9,468,639 (Flibanserin): Scope, Claim Boundaries, and US Landscape

What does US 9,468,639 claim cover in practice?

US Patent 9,468,639 is directed to method-of-treatment claims using flibanserin (or a pharmaceutically acceptable acid addition salt) for the therapeutic indication framed as decreased sexual desire. The independent theme repeats across dependent claim sets: (i) treat the sexual desire condition, (ii) specify patient sex in some claims, and (iii) define administration/amount ranges and dosage unit ranges.

Independent claim focus

Claim 1: “A method of treating decreased sexual desire in a patient” by administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt.

Dependent claim framing

Sex limitations appear as alternatives:
- Claim 2: patient is female
- Claim 3: patient is male
Dose amount ranges (daily or dosage-unit based) appear in multiple forms:
- Claims 4-7: flibanserin daily amount and dosage unit ranges (0.1 mg to 400 mg/day; 1 mg to 300 mg/day; dosage units 0.01 mg to 100 mg; and 0.1 mg to 50 mg)
Claims 8 and onward are structurally similar but shift the condition language (“absent sexual desire,” “inhibited sexual desire”) while tying treatment to the same “decreased sexual desire” treatment outcome.

Condition language variants

Claim 8: “absent sexual desire” but still treats “decreased sexual desire” by administering flibanserin.
Claim 14: “inhibited sexual desire” but still treats “decreased sexual desire.”

This matters because claim scope is anchored to a label-like symptom construct while using multiple descriptive variants. A challenger would typically attack whether these variants are truly distinct or whether they are claim-scope hooks that attempt to capture different clinical wording without changing the active ingredient and dosing mechanics.

How broad are the claims on drug form and dosing?

Active ingredient and salt scope

All asserted claim elements repeatedly cover:

flibanserin, and
pharmaceutically acceptable acid addition salts.

That means any flibanserin formulation that fits the “acid addition salt” category is within literal claim coverage if administered in the claimed manner/amount.

Therapeutically effective amount

The phrase is used in every method claim as the starting point.
Legally, this is typically broad because it does not fix a single dose, but then the dependent claims supply explicit numeric ranges. Practically, the numeric ranges become the clearest boundaries for design-around by dose reduction, dose escalation, or regimen change.

Numeric dose boundaries embedded in dependent claims

The dose language is expressed in three main ways: daily mg ranges, daily dose unit ranges, and dosage unit mg content.

Daily dose ranges

Claim 4: 0.1 mg to 400 mg/day
Claim 5: 1 mg to 300 mg/day
Claim 11: (absent sexual desire) 2 mg to 200 mg/day
Claim 12: (absent sexual desire) 0.1 mg to 100 mg/day
Claim 17: (inhibited sexual desire) 0.1 mg to 400 mg/day

These overlap heavily. Practically, the strictest day-range coverage tends to come from the smallest interval claims (for example, 0.1 mg to 100 mg/day, 2 mg to 200 mg/day), but the presence of wide ranges means many dosing strategies fall in-scope.

Dosage unit content ranges

Claim 6: dosage unit contains 0.01 mg to 100 mg
Claim 7: dosage unit contains 0.1 mg to 50 mg
Claim 13: dosage unit contains 150 mg
Claim 18: dosage unit contains 100 mg
Claim 19: dosage unit contains 80 mg
Claim 20: dosage unit contains 50 mg

This is the main “hook” for formulation strategy. If a generic or competitor could credibly structure a regimen that avoids both: 1) the claimed daily dose bands, and 2) the claimed dosage unit mg content bands, they may create an argument for non-infringement on dependent claims. But the independent claim (Claim 1) remains tethered only to “therapeutically effective amount,” which can still pull many dosing regimens into scope.

What is the likely claim construction pressure around “decreased sexual desire”?

The claims use three overlapping condition labels:

“decreased sexual desire” (Claim 1)
“absent sexual desire” (Claim 8)
“inhibited sexual desire” (Claim 14)

Each dependent claim set then says the method treats “decreased sexual desire.” That drafting choice can reduce a defense argument that the other terms represent different conditions. In infringement terms, this setup often makes it harder to escape liability by rebranding the indication text.

From a practical patent landscape standpoint, this is an attempt to broaden commercial capture around how clinics, sponsors, and marketing materials describe the therapeutic target.

Where are the clear infringement boundaries? (Practical “in-scope vs out-of-scope”)

Below is a direct mapping of claim elements to decision points a competitor would evaluate.

Core element (almost impossible to avoid without changing active ingredient)

Administer flibanserin or an acid addition salt to treat decreased sexual desire.

Design-around by changing salt form is possible only if the new form is not an “acid addition salt,” but the claims already cover “flibanserin or acid addition salt.” Substituting to a different active is the cleanest escape; changing only formulation details is usually insufficient.

Dose element (the primary lever)

A competitor would need to avoid all asserted dependent ranges and create a plausible position that the remaining regimen is not “therapeutically effective” for the claimed use as construed.

Daily dose avoidance: designing to stay outside 0.1-400 mg/day is the most significant. But there are many nested ranges; for example, a regimen outside 0.1-100 mg/day but still within 1-300 mg/day may still hit other dependent claim sets depending on the exact amount.
Dosage unit content avoidance: a competitor would need dosage units that avoid 0.01-100 mg, 0.1-50 mg, and the specific step values 150, 100, 80, 50 mg. Even then, Claim 1 can still be asserted.

Sex limitations

Claim 2/3, 9/10, 15/16 are alternative embodiments. If a regimen is used for either sex, it can still land within some dependent claim coverage.

How does US 9,468,639 position relative to flibanserin’s known commercial narrative?

This patent is aligned with the flibanserin therapeutic area: sexual desire disorders. The use of multiple condition descriptors (“absent,” “inhibited,” “decreased”) and the broad dosing recitation indicates the applicant sought coverage across:

different clinical descriptions used in studies, and
multiple dosage and unit-strength configurations that could arise during development and commercial rollout.

A key point for business planning: because the claims are method claims keyed to administration, they track how a drug is used, not how it is made. That typically makes them more resilient to “process” changes and formulation tweaks unless the design-around affects dose regimen and unit strength enough to avoid dependent claim numeric bands and undermines “therapeutically effective amount” positioning under Claim 1.

What is the actionable patent landscape risk for generic and competitor entries in the US?

Because the dataset provided includes only the claims (not the rest of the patent file, expiry schedule, family details, or prosecution history), the landscape analysis below focuses on what can be stated directly from the claim text: the main risk vector is method-of-treatment infringement by prescribing or administering flibanserin for sexual desire decrease within the claimed dose bands.

Where enforcement pressure typically concentrates for this type of claim

Label-aligned regimens used for the target indication.
Standard daily dosing schedules that fall within 0.1-400 mg/day, which, per the dependent claim coverage, is wide enough to capture many plausible regimens.
Unit strengths in the set that includes 50 mg, 80 mg, 100 mg, 150 mg, and broad ranges up to 100 mg per unit.

Most plausible “avoidance” strategies by dose/unit

If a competitor attempts a non-infringing posture while keeping flibanserin:

Use a dose regimen that sits clearly outside 0.1-400 mg/day for the treated method, or
Use dosage unit strengths outside both:
- 0.01-100 mg and 0.1-50 mg, and
- the specific unit strengths 50/80/100/150 mg,
Reduce dependence on the claimed indication language by using an alternative therapeutic target not captured by “decreased sexual desire” (this is usually weaker because the claims use condition descriptors and “decreased sexual desire” as the treatment outcome in dependent claims 8 and 14).

In practice, step 1 is the only robust numeric escape; steps 2 and 3 often still fail due to Claim 1’s “therapeutically effective amount” breadth.

Claim-by-claim scope map (US 9,468,639)

Claim	Method target condition language	Patient sex	Dose language covered
1	Decreased sexual desire	Not limited	“Therapeutically effective amount” of flibanserin or acid addition salt
2	Decreased sexual desire	Female	Depends on Claim 1 + no further numeric limits in the provided text
3	Decreased sexual desire	Male	Depends on Claim 1 + no further numeric limits in the provided text
4	Decreased sexual desire	Not limited	0.1 mg to 400 mg/day
5	Decreased sexual desire	Not limited	1 mg to 300 mg/day
6	Decreased sexual desire	Not limited	Dosage unit 0.01 mg to 100 mg
7	Decreased sexual desire	Not limited	Dosage unit 0.1 mg to 50 mg
8	Absent sexual desire (treats “decreased sexual desire”)	Not limited	Depends on Claim 1 + no further numeric limits in Claim 8 itself
9	Absent sexual desire (treats “decreased sexual desire”)	Female	No additional numeric limits in the provided text
10	Absent sexual desire (treats “decreased sexual desire”)	Male	No additional numeric limits in the provided text
11	Absent sexual desire (treats “decreased sexual desire”)	Not limited	2 mg to 200 mg/day
12	Absent sexual desire (treats “decreased sexual desire”)	Not limited	0.1 mg to 100 mg/day
13	Absent sexual desire (treats “decreased sexual desire”)	Not limited	Dosage unit about 150 mg
14	Inhibited sexual desire (treats “decreased sexual desire”)	Not limited	Depends on Claim 1
15	Inhibited sexual desire (treats “decreased sexual desire”)	Female	No additional numeric limits in the provided text
16	Inhibited sexual desire (treats “decreased sexual desire”)	Male	No additional numeric limits in the provided text
17	Inhibited sexual desire (treats “decreased sexual desire”)	Not limited	0.1 mg to 400 mg/day
18	Inhibited sexual desire (treats “decreased sexual desire”)	Not limited	Dosage unit about 100 mg
19	Inhibited sexual desire (treats “decreased sexual desire”)	Not limited	Dosage unit about 80 mg
20	Inhibited sexual desire (treats “decreased sexual desire”)	Not limited	Dosage unit about 50 mg

What are the most material business implications?

Substantive breadth on the indication wording. “Decreased,” “absent,” and “inhibited” sexual desire are all pulled into the same treatment outcome frame (“to treat decreased sexual desire”), reducing the value of indication relabeling defenses.
Salt coverage is explicit. Acid addition salts are inside scope, which can limit how far a competitor can move by changing form alone.
Dose bands are wide. Multiple overlapping daily ranges (up to 0.1-400 mg/day) make it difficult to avoid by selecting a “nearby” dosing strategy.
Dosage unit strengths include both broad ranges and specific anchor points. A competitor needs to target both the continuous ranges (0.01-100 mg; 0.1-50 mg) and the discrete unit values (50/80/100/150 mg) to reduce dependent claim risk.
Claim 1 is the enforcement backbone. Even if a competitor argues a regimen does not fall into dependent numeric ranges, Claim 1’s “therapeutically effective amount” can still be asserted.

Key Takeaways

US 9,468,639 is a method-of-treatment patent covering flibanserin (including acid addition salts) used to treat decreased sexual desire, with additional claim embodiments using “absent” and “inhibited” sexual desire language that still ties treatment back to “decreased sexual desire.”
The claim set is broad on active ingredient/salt and broad-to-moderate on dosing, with multiple overlapping dependent dose ranges including 0.1-400 mg/day and dosage unit ranges including 0.01-100 mg and 0.1-50 mg, plus explicit unit anchors at 50, 80, 100, and 150 mg.
The main practical design-around lever is dose regimen and dosage unit strength. Claim 1’s “therapeutically effective amount” still creates pathway risk even where dependent numeric ranges are avoided.

FAQs

1) Can a competitor avoid infringement by changing flibanserin’s salt form?

Only if the new form is not an “acid addition salt.” The claims explicitly cover “flibanserin or a pharmaceutically acceptable acid addition salt thereof.”

2) Does the patent restrict treatment to one sex?

No. Sex-limited dependent claims exist, but they cover both female and male patients through separate claims.

3) Which claim element is the main breadth driver?

Claim 1’s “therapeutically effective amount” combined with the fixed active ingredient and indication framing.

4) Are there narrow numeric dosing traps for dosage unit strength?

Yes. The claims include both ranges (e.g., 0.01-100 mg; 0.1-50 mg) and specific unit contents (about 50 mg, 80 mg, 100 mg, 150 mg).

5) Does changing the clinical wording of the indication help?

The claim set uses multiple descriptors, but dependent claims 8 and 14 still state the method treats “decreased sexual desire,” limiting the value of wording-only differentiation.

References

[1] United States Patent and Trademark Office. US Patent 9,468,639 (flibanserin; method of treating decreased sexual desire).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01125020	Oct 20, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037109	⤷ Start Trial
Argentina	077480	⤷ Start Trial
Austria	327757	⤷ Start Trial
Australia	2002333894	⤷ Start Trial
Brazil	0213358	⤷ Start Trial
Canada	2458067	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,468,639

Summary for Patent: 9,468,639